The Human Vaccines Project: A roadmap for cancer vaccine development

Pedro Romero; Jacques Banchereau; Nina Bhardwaj; Mark Cockett; Mary L Disis; Glenn Dranoff; Eli Gilboa; Scott A Hammond; Robert Hershberg; Alan J Korman; Pia Kvistborg; Cornelis Melief; Ira Mellman; A Karolina Palucka; Irina Redchenko; Harlan Robins; Federica Sallusto; Theodore Schenkelberg; Stephen Schoenberger; Jeffrey Sosman; Özlem Türeci; Benoît Van den Eynde; Wayne Koff; George Coukos

doi:10.1126/scitranslmed.aaf0685

The Human Vaccines Project: A roadmap for cancer vaccine development

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685.

Authors

Pedro Romero¹, Jacques Banchereau², Nina Bhardwaj³, Mark Cockett⁴, Mary L Disis⁵, Glenn Dranoff⁶, Eli Gilboa⁷, Scott A Hammond⁸, Robert Hershberg⁹, Alan J Korman¹⁰, Pia Kvistborg¹¹, Cornelis Melief¹², Ira Mellman¹³, A Karolina Palucka¹⁴, Irina Redchenko¹⁵, Harlan Robins¹⁶, Federica Sallusto¹⁷, Theodore Schenkelberg¹⁸, Stephen Schoenberger¹⁹, Jeffrey Sosman²⁰, Özlem Türeci²¹, Benoît Van den Eynde²², Wayne Koff²³, George Coukos²⁴

Affiliations

¹ Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland.
² The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
³ Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
⁴ Bristol-Myers Squibb, Wallingford, CT06492, USA.
⁵ University of Washington School of Medicine, Seattle, WA 98109-4714, USA.
⁶ Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
⁷ Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.
⁸ MedImmune, Gaithersburg, MD 20878, USA.
⁹ Celgene Immuno-Oncology Center of Excellence, 1616 Eastlake Avenue, Suite 500, Seattle, WA 98102, USA.
¹⁰ Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
¹¹ Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.
¹² ISA Pharmaceuticals & Leiden University Medical Center, 2333 ZA Leiden, Netherlands.
¹³ Genentech, San Francisco, CA 94080, USA.
¹⁴ The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA. Baylor Institute for Immunology Research, Dallas, TX 75204, USA.
¹⁵ Oxford University, Oxford OX3 7DQ, UK.
¹⁶ Adaptive Biotechnologies, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA.
¹⁷ Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
¹⁸ West Monument Consulting, 1906 R Street NW Street 11, Washington, DC 20009, USA.
¹⁹ Center for Personalized Cancer Immunotherapy, La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center, La Jolla, San Diego, CA 92037, USA.
²⁰ Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.
²¹ CI3 Cluster for Individualized Immunotherapy, Kupferbergterasse 17-19, 55131 Mainz, Germany.
²² Ludwig Institute for Cancer Research, Brussels branch, Brussels, BRU 1200, Belgium. Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Woluwe-Saint-Lambert, Belgium. University of Oxford, Nuffield Department of Medicine, Ludwig Institute for Cancer Research, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
²³ International AIDS Vaccines Initiative, 125 Broad Street, 9th Floor, New York, NY 10004, USA.
²⁴ Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland. george.coukos@chuv.ch.

PMID: 27075624
DOI: 10.1126/scitranslmed.aaf0685

Abstract

Cancer vaccine development has been vigorously pursued for 40 years. Immunity to tumor antigens can be elicited by most vaccines tested, but their clinical efficacy remains modest. We argue that a concerted international effort is necessary to understand the human antitumor immune response and achieve clinically effective cancer vaccines.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antigens, Neoplasm / immunology
Cancer Vaccines / immunology*
Humans
Immunologic Memory
T-Lymphocytes / immunology

Substances

Antigens, Neoplasm
Cancer Vaccines

Grants and funding

R01 AI107010/AI/NIAID NIH HHS/United States